Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Treprostinil in Idiopathic Pulmonary Fibrosis
NCT05255991Phase 3Completed
- Sponsor
- United Therapeutics Corporation
- Start
- Sep 2022
- Primary completion
- Jun 2025
- Modality
- Orthosteric Ligands
- Countries
- 16
01
Overview
A Phase 3 trial of treprostinil in idiopathic pulmonary fibrosis (IPF), sponsored by United Therapeutics Corporation. Started Sep 2022; status: completed.
02
Drugs
treprostinil
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05255991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05255991.